A
Angelika Bischof-Delaloye
Researcher at University Hospital of Lausanne
Publications - 24
Citations - 1495
Angelika Bischof-Delaloye is an academic researcher from University Hospital of Lausanne. The author has contributed to research in topics: Ibritumomab tiuxetan & Monoclonal antibody. The author has an hindex of 12, co-authored 24 publications receiving 1440 citations.
Papers
More filters
Journal ArticleDOI
Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma
Franck Morschhauser,John Radford,Achiel Van Hoof,Umberto Vitolo,Pierre Soubeyran,Hervé Tilly,Peter C. Huijgens,Arne Kolstad,Francesco d'Amore,Marcos Gonzalez Diaz,Mario Petrini,Catherine Sebban,Pier Luigi Zinzani,Marinus H. J. van Oers,Wim H. van der Putten,Angelika Bischof-Delaloye,Ama Z. S. Rohatiner,Gilles Salles,Jens Kuhlmann,Anton Hagenbeek +19 more
TL;DR: Consolidation of first remission with yttrium-90 ((90)Y)-ibritumomab tiuxetan in advanced-stage follicular lymphoma is highly effective with no unexpected toxicities, prolonging PFS by 2 years and resulting in high PR-to-CR conversion rates regardless of type of first-line induction treatment.
Journal ArticleDOI
Circulating CD26 is negatively associated with inflammation in human and experimental arthritis.
Nathalie Busso,Nicolai Wagtmann,Christian Herling,Veronique Chobaz-Peclat,Angelika Bischof-Delaloye,Alexander So,Eric Grouzmann +6 more
TL;DR: Low circulating CD26 levels in arthritis may influence CD26-mediated regulation of the chemotactic SDF-1/CXCR4 axis, and plasma levels of DPPIV/CD26 from rheumatoid arthritis patients were significantly decreased when compared to those from osteoarthritis patients and inversely correlate with C-reactive protein levels.
Journal ArticleDOI
Detection of colorectal carcinoma by emission-computerized tomography after injection of 123I-labeled Fab or F(ab')2 fragments from monoclonal anti-carcinoembryonic antigen antibodies.
B. Delaloye,Angelika Bischof-Delaloye,F. Buchegger,V von Fliedner,J. P. Grob,J. C. Volant,J. Pettavel,J P Mach +7 more
TL;DR: The contrast of the tumor images obtained with Fab fragments suggests that this improved method of immunoscintigraphy has the potential to detect early tumor recurrences and thus to increase the survival of patients.
Journal ArticleDOI
90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial
Franck Morschhauser,John Radford,Achiel Van Hoof,Barbara Botto,Ama Z. S. Rohatiner,Gilles Salles,Pierre Soubeyran,Hervé Tilly,Angelika Bischof-Delaloye,Wim L.J. van Putten,Jelle W. Kylstra,Anton Hagenbeek +11 more
TL;DR: Y-ibritumomab consolidation after achieving PR or CR/CRu to induction confers 3-year benefit in median PFS with durable 19% PFS advantage at 8 years and improves TTNT by 5.1 years for patients with advanced FL.
Journal Article
Clinical Value of Immunoscintigraphy in Colorectal Carcinoma Patients: A Prospective Study
Angelika Bischof-Delaloye,B. Delaloye,Franz Buchegger,Willy Gilgien,A. Studer,S. Curchod,Jean-Claude Givel,François Mosimann,Jacques Pettavel,Jean-Pierre Mach +9 more
TL;DR: Radioimmunoscintigraphy with ECT and 123I-labeled anti-CEA MAb allows early detection of recurrence or metastasis of colorectal cancer and contributes to reduced delay between diagnosis and treatment.